Zhejiang Hisoar Pharmaceutical Co., Ltd.

Sümbol: 002099.SZ

SHZ

6.33

CNY

Turuhind täna

-24.3560
P/E suhe
-0.1402
PEG suhe
10.05B
MRK Cap
0.01%
DIV tootlus

Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099-SZ) Finantsaruanded

Q: Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on .

Download

Aastane Quarterly

Lineaarne Log

Diagrammil näete Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist NaN M, mis on NaN % gowth. Kogu perioodi keskmine brutokasum on NaN M, mis on NaN %. Keskmine brutokasumi suhtarv on NaN %. Ettevõtte eelmise aasta tulemuse puhaskasv on NaN %, mis on võrdne NaN % % keskmiselt kogu ettevõtte ajaloo jooksul.,

Aastane Quarterly

10Y 20Y 30Y 40Y

Bilanss

Sukeldudes Zhejiang Hisoar Pharmaceutical Co., Ltd. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja . Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus NaN. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud NaN aruandlusvaluutas. Selle aspekti aastane muutus on NaN%.

common:word.in-mln USD Growth	2022	2020	2018	2016	2014	2012	2010	2008	2006	2004
balance-sheet.row.cash-and-short-term-investments	1420.6	1490.8	1837.4	1969.7	1556.6	1956.1	2977.9	2819.5	727.9	362.3	167.9	194.6	158.2	129.1	123.4	131.7	182	302.7	64.5	55.5	46.2
balance-sheet.row.short-term-investments	-10.7	390.7	9.5	-10.1	-12.8	-14.2	-13.5	-19.1	-20.5	0.1	-1.9	0	0.6	0	0	0	0	0.5	0.8	0.6	4.7
balance-sheet.row.net-receivables	477.7	625.6	627.3	489.1	586.5	644.2	666.3	591.9	445.4	361.6	378.7	336.4	378.5	288.9	233.7	195.3	223.8	112.6	153.8	91.9	119.3
balance-sheet.row.inventory	702.3	1102.4	908	727.4	843	905.4	809.3	631.8	692.6	575	312.1	306	311.4	260.2	211.4	262.1	191.1	183.2	166.3	85.2	48
balance-sheet.row.other-current-assets	25.2	26.8	64.3	53.6	76.4	227.9	82	5.9	34.3	40.4	50.4	29.9	0.9	-25.5	-1.2	-5.5	-7.3	4.5	1.5	4.2	14.7
balance-sheet.row.total-current-assets	2625.7	3245.7	3436.9	3239.9	3062.4	3733.6	4535.5	4049.1	1900.2	1339.3	909.1	866.8	849	652.7	567.3	583.6	589.5	603	386.1	236.8	228.2
balance-sheet.row.property-plant-equipment-net	3029.3	3097.5	2981.2	2561.6	2285.1	1889.5	1475.5	1310.4	1537.6	1474.1	1110.7	915.9	518	431.6	372.9	372.8	301.1	289.9	179.5	134.5	118.3
balance-sheet.row.goodwill	603.3	711	757.7	757.7	757.7	757.7	757.7	757.7	757.7	757.7	0	28.4	0	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	520.8	555.8	490.1	517.9	533.5	539.5	538.9	433.7	452	412.9	73	75	58.8	47	48.1	49.2	50.3	19.9	0	3.9	4.9
balance-sheet.row.goodwill-and-intangible-assets	1124.1	1266.8	1247.9	1275.6	1291.2	1297.3	1296.6	1191.5	1209.7	1170.7	73	103.5	58.8	47	48.1	49.2	50.3	19.9	0	3.9	4.9
balance-sheet.row.long-term-investments	682.4	728.7	249.9	58	80.7	82.1	94.6	220.2	44.8	28.3	6.3	4.4	5.4	0	0	0	0	8.5	10.1	11.1	6.3
balance-sheet.row.tax-assets	41.6	52.3	52.2	42.2	27.3	32.5	27.8	23.7	25.3	16.3	6.3	5.2	3.3	5.8	3.9	3	3.6	0	0	0	0
balance-sheet.row.other-non-current-assets	17	2.1	51.8	1.4	0.5	0.5	36.9	110.8	113.1	138.8	4.1	22.2	0.6	3.2	4.1	4.4	5.2	0.6	1	1.1	4.7
balance-sheet.row.total-non-current-assets	4894.4	5147.4	4583	3938.7	3684.8	3301.8	2931.4	2856.5	2930.5	2828.2	1200.4	1051.2	586.1	487.6	429	429.4	360.2	318.9	190.6	150.6	134.2
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	7520.1	8393.1	8019.9	7178.6	6747.2	7035.4	7466.9	6905.6	4830.8	4167.4	2109.5	1918	1435.1	1140.3	996.3	1013.1	949.8	921.9	576.7	387.4	362.4
balance-sheet.row.account-payables	603.3	995	1028.8	613.2	601.7	791.9	733.2	372.6	286.5	401.4	396.7	378.5	241.5	225.1	176.3	211	174.2	124.7	137.2	42.7	58.3
balance-sheet.row.short-term-debt	1043.3	838.3	574.4	430.4	200.3	643.1	1343	752	612.6	305	496.1	245.9	255	157	210.3	255.8	231.5	249	226.2	148.4	111.5
balance-sheet.row.tax-payables	27.1	23.5	37.7	43.7	44.8	54.9	37.4	34.5	45.6	91	4.1	3.5	8	2.3	-8.5	-22.7	-12.5	0.9	-5.8	0.1	4.6
balance-sheet.row.long-term-debt-total	10.2	162.1	17.8	22	0	0	100.4	200	187.8	70	477.8	485.1	160	78.1	30	0	0	2.4	6.9	38	59
Deferred Revenue Non Current	57.3	54.4	53.4	48.3	50.6	44.7	38.4	27.7	27.4	25	21.9	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	1.2	129.2	1.2	1.4	12.9	89.2	5.5	507.1	26	13.1	1	4.8	1.8	7.7	0.9	4.3	3.4	4.2	3.9	2.9	2.3
balance-sheet.row.total-non-current-liabilities	111.5	317.5	173.6	144.7	82.5	65.8	140.2	381.3	216.9	122.3	501	498.7	161.6	79.4	32	1.4	1.3	2.4	7.6	38	71.7
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	10.2	14	17.8	22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-liab	1918.4	2288.2	1906.3	1326.5	1022.7	1644.8	2324.9	2135.3	1258	988.7	1476.7	1180	698.2	502.3	434.5	465.6	411.7	402.7	393.8	255.3	277.4
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	1618.7	1618.7	1618.7	1618.7	1618.7	1618.8	1621.6	1622.8	759.8	723	324.5	324.5	161.5	160.5	160.5	160.5	160.5	107	43.8	43.8	30
balance-sheet.row.retained-earnings	816.5	1329.6	1410.8	1362.9	1525.3	1232.5	897.8	618.5	562.7	211.1	168.8	250.9	279	208.5	147.4	136.3	128.8	110.4	73.7	31.6	39
balance-sheet.row.accumulated-other-comprehensive-income-loss	279.6	268.1	344.2	279.5	226.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-total-stockholders-equity	2891.6	2891.6	2741.3	2591	2354.1	2539.2	2622.6	2526.5	2263.1	2250.2	129.8	136.3	288.4	265.9	250.9	247.9	245.7	299.2	63.6	53.4	12.9
balance-sheet.row.total-stockholders-equity	5606.4	6108	6115	5852.1	5724.5	5390.5	5142	4767.7	3585.5	3184.4	623.1	711.7	728.8	634.9	558.9	544.6	535.1	516.7	181	128.8	81.9
balance-sheet.row.total-liabilities-and-stockholders-equity	7520.1	8393.1	8019.9	7178.6	6747.2	7035.4	7466.9	6905.6	4830.8	4167.4	2109.5	1918	1435.1	1140.3	996.3	1013.1	949.8	921.9	576.7	387.4	362.4
balance-sheet.row.minority-interest	-4.6	-3.1	-1.4	0	0	0	0	2.6	-12.8	-5.6	9.7	26.3	8.1	3.2	2.9	2.9	3	2.6	1.9	3.3	3.1
balance-sheet.row.total-equity	5601.7	6104.9	6113.6	5852.1	5724.5	5390.5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	671.7	720.9	259.4	47.9	67.9	67.9	81.1	201	24.3	28.4	4.4	4.4	6	3.2	4.1	4.4	5.2	9	10.9	11.6	10.9
balance-sheet.row.total-debt	1053.5	1000.5	592.2	430.4	200.3	643.1	1343	952	612.6	375	973.9	731	415	235.1	240.3	255.8	231.5	251.4	233.1	186.4	170.6
balance-sheet.row.net-debt	-367.1	-490.4	-1235.7	-1539.3	-1356.3	-1313	-1634.9	-1867.5	-115.3	12.8	806	536.4	257.4	106	116.9	124.1	49.5	-50.9	169.4	131.4	129

Rahavoogude aruanne

Zhejiang Hisoar Pharmaceutical Co., Ltd. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab NaN nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides NaN, mis tähistab NaN erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli NaN. See on NaN nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte NaN, NaN, NaN, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid NaN, kusjuures erinevus võrreldes eelmise aastaga oli NaN. Lisaks eraldas ettevõte NaN aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui NaN, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln USD Growth	2021	2019	2017	2015	2013	2011	2009	2007	2005	2003
cash-flows.row.net-income	86.1	93.9	319.7	770.8	605	342.4	224.6	509.5	44.7	-99.3	20.2	104	85.9	30.4	25.5	31.4	52.8	50.4	35.7	22.9
cash-flows.row.depreciation-and-amortization	336.5	294.2	256.6	203.1	192.4	181.3	197.9	181	117.9	82.8	60.7	54.2	49.2	43.8	37.8	28.5	21.2	16.8	13.4	9.6
cash-flows.row.deferred-income-tax	-1.6	-3.1	48.7	27.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.stock-based-compensation	62.6	200.4	37.6	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.change-in-working-capital	-377.5	-350.2	-142	-387.8	-14.8	-564.9	-79.2	-269.1	-34.7	-17.4	64.7	-79.5	21.1	4.1	-50.9	-27.6	-26.6	-49.1	-14.9	-45
cash-flows.row.account-receivables	-229.8	-755	-353.2	-276.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.inventory	-213.7	-194.1	102.1	52.6	-99.3	-177.1	12.7	-145.9	-121.4	-18.2	42.5	-69.7	-69.9	49.7	-74	-8.1	-13.9	-86.4	-37.4	-1
cash-flows.row.account-payables	67.6	602	60.3	-191.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-working-capital	-1.6	-3.1	48.7	27.5	84.5	-387.9	-91.9	-123.2	86.7	0.7	22.2	-9.8	91	-45.6	23.1	-19.5	-12.7	37.3	22.5	-44
cash-flows.row.other-non-cash-items	9.9	-132.9	13.4	-8.2	8.9	143.9	286.2	40.9	63.7	94.7	35.1	13.9	24.7	20.1	18.2	18.8	14.5	18	8.2	7.1
cash-flows.row.net-cash-provided-by-operating-activities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-179.4	-229.6	-74.2	-160.6	-255.8	-149	-124.3	-296.4	-169.1	-281.8	-426.8	-217.5	-146.5	-53.6	-90.4	-112.6	-102.6	-73.7	-42.5	-43.9
cash-flows.row.acquisitions-net	5.9	0.2	3.7	5	0	51	62.8	0	4.5	0	0	-2.5	0.4	0	0	113.5	102.6	0	4.5	44.7
cash-flows.row.purchases-of-investments	-464.1	-251.5	-0.1	-20	0	-10	-148.6	0	0	-2	0	0	0	0	0	-0.5	-0.8	-1.4	-0.5	-7.8
cash-flows.row.sales-maturities-of-investments	5	2.5	-3.7	1160	0	143.7	4.5	0	0	27.1	0	0	0	0	0.5	1.1	1.2	0	4.8	4.4
cash-flows.row.other-investing-activites	12.3	-30.6	3.7	-247.8	-841.6	-8.2	-11.1	5.5	154.3	17	29.9	6.1	0.7	0.9	0.3	-112.6	-102.6	0.1	-0.1	-43.9
cash-flows.row.net-cash-used-for-investing-activites	-620.3	-509	-70.6	736.6	-1097.4	27.5	-216.7	-290.9	-10.4	-239.7	-396.9	-213.9	-145.4	-52.7	-89.6	-111.1	-102.1	-75	-33.8	-46.5
cash-flows.row.debt-repayment	-1817	-929	-230	-683.7	-1500	-1931.1	-1465.4	-521	-1323.1	-465.5	-538.6	-344.6	-404.6	-369.6	-313.8	-352.8	-392.5	-264.4	-176	-104.2
cash-flows.row.common-stock-issued	0	0	236.9	20.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.common-stock-repurchased	0	0	-236.9	-20.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	-195.4	-53.4	-478.1	-483.4	-204.6	-104.2	-199.3	-170.2	-53.8	-51.4	-79.1	-49.3	-26.6	-29	-31.9	-28.5	-27.5	-11.5	-11	-6.9
cash-flows.row.other-financing-activites	1890.6	1063.2	696.9	264.7	798.3	1506.3	3287.6	929	1374.1	695	824.8	539.8	399.4	374.1	318.1	330.8	700.4	311.1	191.8	165.3
cash-flows.row.net-cash-used-provided-by-financing-activities	-121.9	80.8	-11.2	-902.3	-906.3	-529	1622.9	237.7	-2.8	178.1	207.1	145.9	-31.8	-24.5	-27.6	-50.5	280.4	35.2	4.8	54.3
cash-flows.row.effect-of-forex-changes-on-cash	75.1	-25.5	-38.5	9.9	35.7	-97.8	-0.1	-0.2	0.3	0	0	0	0	0	0	0	0	0	0	-0.1
cash-flows.row.net-change-in-cash	-551	-351.4	413.6	456.6	-1176.6	-496.5	2035.5	408.9	178.7	-0.7	-9	24.7	3.7	21.2	-86.5	-110.4	240.2	-3.7	13.4	2.1
cash-flows.row.cash-at-end-of-period	1037	1588	1939.4	1525.8	1069.2	2245.8	2742.3	706.8	297.9	119.2	119.9	128.9	104.3	100.6	79.4	165.9	276.3	51.2	54.9	41.5
cash-flows.row.cash-at-beginning-of-period	1588	1939.4	1525.8	1069.2	2245.8	2742.3	706.8	297.9	119.2	119.9	128.9	104.3	100.6	79.4	165.9	276.3	36.1	54.9	41.5	39.4
cash-flows.row.operating-cash-flow	116.1	102.4	533.9	612.4	791.4	102.7	629.4	462.2	191.6	60.9	180.7	92.6	180.9	98.4	30.6	51.1	61.9	36.1	42.4	-5.5
cash-flows.row.capital-expenditure	-179.4	-229.6	-74.2	-160.6	-255.8	-149	-124.3	-296.4	-169.1	-281.8	-426.8	-217.5	-146.5	-53.6	-90.4	-112.6	-102.6	-73.7	-42.5	-43.9
cash-flows.row.free-cash-flow	-63.3	-127.2	459.7	451.8	535.7	-46.3	505.1	165.8	22.5	-220.9	-246.1	-124.9	34.4	44.8	-59.8	-61.5	-40.7	-37.7	-0.2	-49.4

Kasumiaruande rida

Zhejiang Hisoar Pharmaceutical Co., Ltd. tulud muutusid võrreldes eelmise perioodiga NaN%. 002099.SZ brutokasum on teatatud NaN. Ettevõtte tegevuskulud on NaN, mille muutus võrreldes eelmise aastaga on NaN%. Kulud amortisatsioonikulud on NaN, mis on NaN% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on NaN, mis on NaN% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on NaN, mis tähendab NaN% kasvu võrreldes eelmise aastaga. Tegevustulu on NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on NaN%. Eelmise aasta puhaskasum oli NaN.

common:word.in-mln USD Growth	2022	2020	2018	2016	2014	2012	2010	2008	2006	2004
income-statement-row.row.total-revenue	2171.9	2704.1	2484.8	2471.4	2941.4	2718.6	2308.9	2433.9	2464.5	1319.1	1160.7	1145.4	1298.4	1074.6	893.4	1063	1034.9	770.2	690.8	506.1	373.7
income-statement-row.row.cost-of-revenue	1867.2	1983.9	1559.4	1348.8	1463.2	1511.9	1317.4	1368.3	1325.2	908.3	946.5	920.9	986.6	791.9	726.2	924.3	894.6	633.2	552.7	412.1	306.7
income-statement-row.row.gross-profit	304.6	720.3	925.4	1122.6	1478.3	1206.7	991.5	1065.5	1139.3	410.8	214.2	224.5	311.8	282.6	167.2	138.7	140.3	137	138	94	67.1
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	-34	295.5	477.5	389.5	297.4	-8.5	-4.8	9.7	12.1	4.7	10.1	22.7	7.3	4.9	1.9	0.4	0.8	3.5	-2.4	-1.3	1.1
income-statement-row.row.operating-expenses	471	570	770.6	658.4	568.1	524.8	480.6	555.3	522.2	286.9	218.8	184.1	172.7	157	112.7	84.6	71.1	46.1	50.1	33.9	30.6
income-statement-row.row.cost-and-expenses	2338.3	2553.9	2330	2007.2	2031.2	2036.7	1798	1923.6	1847.3	1195.2	1165.3	1105	1159.3	948.9	838.9	1008.9	965.7	679.3	602.9	446	337.2
income-statement-row.row.interest-income	68.1	33.5	33	30.9	41.8	44.4	37.1	7.5	1.5	4.4	2.2	1.6	1.3	1.1	0	0	0	2	0.6	1.1	0
income-statement-row.row.interest-expense	37.8	36.5	21.9	11.4	15.5	42.6	55	51.1	18.6	58.2	44.2	29.3	13.9	10.5	14.8	22.2	15.4	16.3	11.6	10.9	6.5
income-statement-row.row.selling-and-marketing-expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	-2	-139.6	1	-1.8	-6.4	15.4	-111.1	-175.6	7.1	-58.6	-93.5	-15.8	-12.3	-25.3	-20.2	-24.4	-20.7	-18.5	-15.7	-10.7	-4.2
income-statement-row.row.ebitda-ratio-caps	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	-34	295.5	477.5	389.5	297.4	-8.5	-4.8	9.7	12.1	4.7	10.1	22.7	7.3	4.9	1.9	0.4	0.8	3.5	-2.4	-1.3	1.1
income-statement-row.row.total-operating-expenses	-2	-139.6	1	-1.8	-6.4	15.4	-111.1	-175.6	7.1	-58.6	-93.5	-15.8	-12.3	-25.3	-20.2	-24.4	-20.7	-18.5	-15.7	-10.7	-4.2
income-statement-row.row.interest-expense	37.8	36.5	21.9	11.4	15.5	42.6	55	51.1	18.6	58.2	44.2	29.3	13.9	10.5	14.8	22.2	15.4	16.3	11.6	10.9	6.5
income-statement-row.row.depreciation-and-amortization	364.6	336.5	333	280.4	226.2	192.4	181.3	197.9	181	117.9	82.8	60.7	54.2	49.2	43.8	37.8	28.5	21.2	16.8	13.4	9.6
income-statement-row.row.ebitda-caps	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	-464.2	240.4	122	395.3	918.8	710.9	399.7	327.3	613.2	61.3	-102.7	3.3	120.9	99.8	34	29.8	47.7	74.1	77.3	51.6	32.7
income-statement-row.row.income-before-tax	-466.2	100.8	123	393.5	912.5	697.3	399.9	334.7	624.2	65.3	-98.1	24.6	126.9	100.3	34.3	29.7	48.5	75	73.6	49.9	33
income-statement-row.row.income-tax-expense	-44.6	14.7	29.2	73.8	141.7	92.3	57.5	110.2	114.7	20.6	1.2	4.4	22.8	14.5	4	4.2	17.1	22.2	23.2	14.2	10.2
income-statement-row.row.net-income	-420.1	88	95.2	319.7	770.8	605	342.2	225	516.6	53.5	-82.1	22.8	105.1	85.6	30.3	25.6	31.1	52.1	49.6	35.1	22.4